Alectinib monotherapy (ALK+ NSCLC, 1L metastatic OR adjuvant)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-ALECTINIB |
|---|
| ID | REG-ALECTINIB-NSCLC |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
ALEX: superior to crizotinib 1L (PFS 35 vs 11 months; intracranial response 81 vs 50%). ALINA: 2-year adjuvant in ALK+ stage IB-IIIA resected.
Used By
Indication
IND-NSCLC-ALK-MAINT-ALECTINIB- IND-NSCLC-ALK-MAINT-ALECTINIBIND-NSCLC-ALK-MET-1L- IND-NSCLC-ALK-MET-1L